A Phase 2 interventional study of Herpes zoster vaccine GSK1437173A and Placebo in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 12 sites in 3 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-26.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.
Among the 46 studies testing shingrix in Herpes Zoster, this one is the 18th largest by enrollment, is one of 2 that started in 2009, is one of 8 in phase 2, and was the 1st registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
Loyola University · Sites in United States
University of Colorado, Denver · Sites in United States
Ages 18–70
By country, each count listing its studies:
shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 22 · Phase 4 8
First in 2009; this study’s year is marked. 2 started in 2009.
This study's enrollment of 410 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 239 across the 46 interventional studies. Of the 32 that completed or were terminated, 27 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
44 studies in Herpes Zoster by GlaxoSmithKline: 3 open now, 5 under way, 1 of them phase 3. Of 39 finished, 34 (87%) have results posted.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 21st largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2009, is one of 8 in phase 2, and was the 5th registered.
GlaxoSmithKline’s Herpes Zoster studies by the year they started, since 2007.
4 of the studies testing shingrix in Herpes Zoster that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
| NCT05580458National Institute of Allergy and Infectious Diseases (NIAID)Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population | 2027-02-01 |
| NCT06162494Ann & Robert H Lurie Children's Hospital of ChicagoRecombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients | 2027-03-31 |
| NCT06569823Dynavax Technologies CorporationSafety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies testing shingrix in Herpes Zoster, from their registry updates:
Among GlaxoSmithKline’s 44 in Herpes Zoster:
This tab as a report to print or save as PDF → With an account.
The goal of this randomized observer-blind trial is to further refine the formulation of vaccines containing GSK1437173A in older adults by comparing the cellular and humoral immune responses and the safety profiles of the different formulations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
Biological: Herpes zoster vaccine GSK1437173A
Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) GSK1437173A formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
Biological: Herpes zoster vaccine GSK1437173A
Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
Biological: Herpes zoster vaccine GSK1437173A
Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
Biological: Placebo
2 vaccinations at Months 0 and 2 with GSK1437173A (different formulations)
Also known as: gE/AS01E, gE/AS01B
2 vaccinations at Months 0 and 2 with placebo
Also known as: Placebo/Saline
Frequency of gE-specific Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Different Immunological Activation Markers
The analysis focused on CD4+ T-cells expressing at least 2 immunological activation markers among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L). Frequencies were determined by in vitro Intracellular Cytokine Staining (ICS).
Time frame: One month after the second vaccination (Month 3)
Frequency of Varicella-Zoster Virus (VZV)-Specific CD4+ T-cells Expressing at Least 2 Different Immunological Activation Markers
The analysis focused on CD4+ T-cells expressing at least 2 immunological activation markers among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L). Frequencies were determined by in vitro Intracellular Cytokine Staining (ICS).
Time frame: One month after the second vaccination (Month 3)
Anti-glycoprotein E (gE) Antibody Concentrations
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).
Time frame: One month after the second vaccination (Month 3)
Anti-VZV Antibody Concentrations
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).
Time frame: One month after the second vaccination (Month 3)
Frequencies of gE-specific CD4+ T-cells Expressing at Least 2 Different Immunological Activation Markers
The analysis focused on CD4+ T-cells expressing at least 2 immunological activation markers among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L). Frequencies were determined by in vitro Intracellular Cytokine Staining (ICS).
Time frame: At Month 0 and at Month 2
Frequency of VZV-specific CD4+ T-cells Expressing at Least 2 Different Immunological Activation Markers
The analysis focused on CD4+ T-cells expressing at least 2 immunological activation markers among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L). Frequencies were determined by in vitro Intracellular Cytokine Staining (ICS).
Time frame: At Month 0 and at Month 2
Anti-gE Antibody Concentrations
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).
Time frame: At Month 0 and at Month 2
Anti-VZV Antibody Concentrations
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).
Time frame: At Month 0 and at Month 2
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: During the 7-day (Days 0-6) post-vaccination period after each dose and across doses
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia and fever \[defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever higher than (\>) 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 7-day (Days 0-6)post-vaccination period after each dose and across doses
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: Within the 30-day (Days 0-29) post-vaccination period
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From Month 0 up to Month 8
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: During the period after Month 8 up to the end of the study at Month 14
Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs)
Any new onset of autoimmune diseases were to be reported throughout the entire study period, whether or not they were considered to be possibly related to the treatment administration. These included neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events, autoimmune bullous skin diseases, vasculitis and liver autoimmune diseases.
Time frame: From Month 0 until Month 8
Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs)
Any new onset of autoimmune diseases were to be reported throughout the entire study period, whether or not they were considered to be possibly related to the treatment administration. These included neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events, autoimmune bullous skin diseases, vasculitis and liver autoimmune diseases.
Time frame: During the period after Month 8 up to the end of the study at Month 14
Number of Subjects With Suspected Cases of Herpes Zoster (HZ)
A suspected case of HZ was defined as a rash consistent with HZ.
Time frame: From Month 0 until Month 8
Number of Subjects With Suspected Cases of Herpes Zoster (HZ)
A suspected case of HZ is defined as a rash consistent with HZ.
Time frame: During the period after Month 8 up to the end of the study at Month 14
Number of Subjects With Haematological and Biochemical Parameters Unknown, Below, Within or Above the Normal Ranges
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hematocrit (HCT), Hemoglobin (HGB), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Mean Corpuscular Volume (MCV), Monocytes (MON), Neutrophils (NEU), Partial Thromboplastin Time (PTT), Platelets (PLAT), Prothrombin Time (PT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
Time frame: At Month 0
Number of Subjects With Haematological and Biochemical Parameters Unknown, Below, Within or Above the Normal Ranges
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hematocrit (HCT), Hemoglobin (HGB), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Mean Corpuscular Volume (MCV), Monocytes (MON), Neutrophils (NEU), Partial Thromboplastin Time (PTT), Platelets (PLAT), Prothrombin Time (PT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
Time frame: At Month 2
Number of Subjects With Haematological and Biochemical Parameters Unknown, Below, Within or Above the Normal Ranges
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hematocrit (HCT), Hemoglobin (HGB), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Mean Corpuscular Volume (MCV), Monocytes (MON), Neutrophils (NEU), Partial Thromboplastin Time (PTT), Platelets (PLAT), Prothrombin Time (PT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
Time frame: At Month 3
| Milestone | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| Started | 38 | 73 | 149 | 150 |
| Completed | 38 | 70 | 142 | 141 |
| Not completed | 0 | 3 | 7 | 9 |
| Withdrew: Adverse event | 0 | 1 | 1 | 2 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 | 5 |
| Withdrew: Lost to follow-up | 0 | 1 | 2 | 2 |
| Withdrew: Other | 0 | 0 | 1 | 0 |
| Milestone | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| Started | 34 | 65 | 130 | 126 |
| Completed | 33 | 63 | 129 | 126 |
| Not completed | 1 | 2 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
The analysis focused on CD4+ T-cells expressing at least 2 immunological activation markers among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L). Frequencies were determined by in vitro Intracellular Cytokine Staining (ICS).
| gE-specific CD4+ T-cells/million T-cells | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| Frequency of gE-specific Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Different Immunological Activation Markers | 231.82 ± 411.84 | 570.36 ± 610.10 | 2172.37 ± 1805.51 | 2582.80 ± 2154.92 |
The analysis focused on CD4+ T-cells expressing at least 2 immunological activation markers among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L). Frequencies were determined by in vitro Intracellular Cytokine Staining (ICS).
| VZV-specific CD4+ T-cells/million T-cell | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| Frequency of Varicella-Zoster Virus (VZV)-Specific CD4+ T-cells Expressing at Least 2 Different Immunological Activation Markers | 457.43 ± 275.25 | 523.12 ± 396.01 | 1093.08 ± 927.18 | 1270.79 ± 1106.45 |
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).
| mIU/mL | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| Anti-glycoprotein E (gE) Antibody Concentrations | 1987.0 (1405.8 to 2808.6) | 14627.6 (11347.9 to 18855.1) | 49531.5 (44269.3 to 55419.2) | 68798.2 (61596.8 to 76841.5) |
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).
| mIU/mL | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| Anti-VZV Antibody Concentrations | 1423.2 (1097.8 to 1845.0) | 2786.4 (2445.1 to 3175.3) | 4565.4 (4357.0 to 4783.7) | 4972.8 (4802.7 to 5148.8) |
The analysis focused on CD4+ T-cells expressing at least 2 immunological activation markers among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L). Frequencies were determined by in vitro Intracellular Cytokine Staining (ICS).
| gE-specific CD4+ T-cells/million T-cells | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| Month 0 | 210.18 ± 363.37 | 130.98 ± 115.90 | 196.52 ± 217.94 | 173.48 ± 203.54 |
| Month 2 | 185.59 ± 310.06 | 189.46 ± 188.80 | 463.79 ± 386.94 | 430.50 ± 323.88 |
The analysis focused on CD4+ T-cells expressing at least 2 immunological activation markers among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L). Frequencies were determined by in vitro Intracellular Cytokine Staining (ICS).
| VZV-specific CD4+ T-cells/million T-cell | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| Month 0 | 533.97 ± 422.46 | 352.71 ± 283.42 | 457.28 ± 402.04 | 482.63 ± 512.05 |
| Month 2 | 491.12 ± 330.34 | 410.69 ± 356.65 | 595.10 ± 588.51 | 574.54 ± 586.85 |
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).
| mIU/mL | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| Month 0 | 1907.7 (1374.9 to 2646.9) | 1640.3 (1307.9 to 2057.3) | 1526.7 (1306.6 to 1783.8) | 1398.3 (1212.6 to 1612.5) |
| Month 2 | 2022.3 (1484.6 to 2754.7) | 10022.8 (7593.7 to 13228.7) | 19962.3 (16894.4 to 23587.3) | 23942.4 (20536.9 to 27912.6) |
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).
| mIU/mL | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| Month 0 | 1505.5 (1191.7 to 1901.9) | 1289.6 (1100.3 to 1511.6) | 1215.9 (1077.4 to 1372.2) | 1175.8 (1051.0 to 1315.5) |
| Month 2 | 1365.5 (1074.4 to 1735.4) | 2392.8 (2074.8 to 2759.5) | 3125.6 (2902.8 to 3365.5) | 3355.1 (3110.6 to 3618.9) |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
| Participants | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| Any Pain, Dose 1 | 1 | 8 | 89 | 112 |
| Grade 3 Pain, Dose 1 | 0 | 0 | 1 | 0 |
| Any Redness, Dose 1 | 0 | 0 | 15 | 26 |
| Grade 3 Redness, Dose 1 | 0 | 0 | 2 | 2 |
| Any Swelling, Dose 1 | 0 | 1 | 9 | 8 |
| Grade 3 Swelling, Dose 1 | 0 | 0 | 1 | 0 |
| Any Pain, Dose 2 | 2 | 9 | 82 | 106 |
| Grade 3 Pain, Dose 2 | 0 | 0 | 1 | 6 |
| Any Redness, Dose 2 | 0 | 3 | 19 | 37 |
| Grade 3 Redness, Dose 2 | 0 | 0 | 1 | 1 |
| Any Swelling, Dose 2 | 0 | 2 | 20 | 18 |
| Grade 3 Swelling, Dose 2 | 0 | 0 | 0 | 1 |
| Any Pain, Across Doses | 3 | 14 | 104 | 125 |
| Grade 3 Pain, Across Doses | 0 | 0 | 2 | 6 |
| Any Redness, Across Doses | 0 | 3 | 26 | 44 |
| Grade 3 Redness, Across Doses | 0 | 0 | 3 | 2 |
| Any Swelling, Across Doses | 0 | 3 | 25 | 23 |
| Grade 3 Swelling, Across Doses | 0 | 0 | 1 | 1 |
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia and fever \[defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever higher than (\>) 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
| Participants | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| Any Fatigue, Dose 1 | 3 | 10 | 32 | 42 |
| Grade 3 Fatigue, Dose 1 | 0 | 1 | 2 | 2 |
| Related Fatigue, Dose 1 | 3 | 9 | 28 | 39 |
| Any Gastr. sympt., Dose 1 | 1 | 1 | 10 | 8 |
| Grade 3 Gastr. sympt., Dose 1 | 1 | 0 | 2 | 0 |
| Related Gastr. sympt., Dose 1 | 0 | 0 | 7 | 7 |
| Any Headache, Dose 1 | 2 | 8 | 22 | 32 |
| Grade 3 Headache, Dose 1 | 0 | 0 | 0 | 1 |
| Related Headache, Dose 1 | 1 | 5 | 14 | 29 |
| Any Myalgia, Dose 1 | 1 | 8 | 36 | 42 |
| Grade 3 Myalgia, Dose 1 | 0 | 0 | 0 | 2 |
| Related Myalgia, Dose 1 | 1 | 6 | 29 | 40 |
| Any Temperature, Dose 1 | 0 | 0 | 7 | 11 |
| Grade 3 Temperature, Dose 1 | 0 | 0 | 0 | 0 |
| Related Temperature, Dose 1 | 0 | 0 | 3 | 8 |
| Any Fatigue, Dose 2 | 5 | 10 | 41 | 58 |
| Grade 3 Fatigue, Dose 2 | 1 | 1 | 3 | 7 |
| Related Fatigue, Dose 2 | 3 | 9 | 34 | 56 |
| Any Gastr. sympt., Dose 2 | 2 | 4 | 12 | 12 |
| Grade 3 Gastr. sympt., Dose 2 | 0 | 0 | 0 | 0 |
| Related Gastr. sympt., Dose 2 | 1 | 3 | 8 | 9 |
| Any Headache, Dose 2 | 3 | 5 | 25 | 42 |
| Grade 3 Headache, Dose 2 | 0 | 0 | 0 | 4 |
| Related Headache, Dose 2 | 1 | 5 | 20 | 38 |
| Any Myalgia, Dose 2 | 2 | 8 | 33 | 49 |
| Grade 3 Myalgia, Dose 2 | 1 | 0 | 2 | 6 |
| Related Myalgia, Dose 2 | 2 | 8 | 26 | 48 |
| Any Temperature, Dose 2 | 1 | 0 | 14 | 21 |
| Grade 3 Temperature, Dose 2 | 0 | 0 | 0 | 0 |
| Related Temperature, Dose 2 | 1 | 0 | 11 | 20 |
| Any Fatigue, Across Doses | 7 | 16 | 52 | 72 |
| Grade 3 Fatigue, Across Doses | 1 | 2 | 5 | 9 |
| Related Fatigue, Across Doses | 6 | 14 | 45 | 71 |
| Any Gastr. sympt., Across Doses | 3 | 5 | 18 | 17 |
| Grade 3 Gastr. sympt., Across Doses | 1 | 0 | 2 | 0 |
| Related Gastr. sympt., Across Doses | 1 | 3 | 12 | 15 |
| Any Headache, Across Doses | 4 | 10 | 37 | 56 |
| Grade 3 Headache, Across Doses | 0 | 0 | 0 | 5 |
| Related Headache, Across Doses | 2 | 8 | 29 | 53 |
| Any Myalgia, Across Doses | 2 | 12 | 49 | 62 |
| Grade 3 Myalgia, Across Doses | 1 | 0 | 2 | 7 |
| Related Myalgia, Across Doses | 2 | 11 | 41 | 62 |
| Any Temperature, Across Doses | 1 | 0 | 18 | 25 |
| Grade 3 Temperature, Across Doses | 0 | 0 | 0 | 0 |
| Related Temperature, Across Doses | 1 | 0 | 13 | 23 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
| Participants | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| Any AE(s) | 6 | 18 | 37 | 46 |
| Grade 3 AE(s) | 1 | 1 | 3 | 5 |
| Related AE(s) | 0 | 2 | 15 | 24 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| Up to Month 3 | 2 | 3 | 4 | 4 |
| After Month 3 up to Month 8 | 1 | 4 | 2 | 2 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 1 | 3 | 1 | 4 |
Any new onset of autoimmune diseases were to be reported throughout the entire study period, whether or not they were considered to be possibly related to the treatment administration. These included neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events, autoimmune bullous skin diseases, vasculitis and liver autoimmune diseases.
| Participants | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) | 0 | 0 | 0 | 0 |
Any new onset of autoimmune diseases were to be reported throughout the entire study period, whether or not they were considered to be possibly related to the treatment administration. These included neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events, autoimmune bullous skin diseases, vasculitis and liver autoimmune diseases.
| Participants | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) | 0 | 0 | 0 | 0 |
A suspected case of HZ was defined as a rash consistent with HZ.
| Participants | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| Number of Subjects With Suspected Cases of Herpes Zoster (HZ) | 0 | 0 | 0 | 0 |
A suspected case of HZ is defined as a rash consistent with HZ.
| Participants | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| Number of Subjects With Suspected Cases of Herpes Zoster (HZ) | 0 | 0 | 0 | 0 |
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hematocrit (HCT), Hemoglobin (HGB), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Mean Corpuscular Volume (MCV), Monocytes (MON), Neutrophils (NEU), Partial Thromboplastin Time (PTT), Platelets (PLAT), Prothrombin Time (PT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
| Participants | Placebo Group | GSK1437173A Formulation 1 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 3 Group |
|---|---|---|---|---|
| ALT — Unknown | 0 | 0 | 0 | 0 |
| ALT — Below | 0 | 0 | 0 | 0 |
| ALT — Normal | 35 | 146 | 142 | 71 |
| ALT — Above | 3 | 4 | 7 | 2 |
| AST — Unknown | 0 | 0 | 0 | 0 |
| AST — Below | 0 | 0 | 0 | 0 |
| AST — Normal | 38 | 148 | 146 | 71 |
| AST — Above | 0 | 2 | 3 | 2 |
| BAS — Unknown | 1 | 2 | 1 | 0 |
| BAS — Below | 0 | 0 | 0 | 0 |
| BAS — Normal | 37 | 148 | 148 | 73 |
| BAS — Above | 0 | 0 | 0 | 0 |
| CAL — Unknown | 0 | 0 | 0 | 0 |
| CAL — Below | 0 | 0 | 0 | 0 |
| CAL — Normal | 38 | 150 | 144 | 73 |
| CAL — Above | 0 | 0 | 5 | 0 |
| CREA — Unknown | 0 | 0 | 0 | 0 |
| CREA — Below | 0 | 0 | 0 | 0 |
| CREA — Normal | 36 | 144 | 142 | 70 |
| CREA — Above | 2 | 6 | 7 | 3 |
| EOS — Unknown | 1 | 2 | 1 | 0 |
| EOS — Below | 0 | 11 | 12 | 8 |
| EOS — Normal | 36 | 132 | 135 | 65 |
| EOS — Above | 1 | 5 | 1 | 0 |
| FIBR — Unknown | 0 | 3 | 2 | 1 |
| FIBR — Below | 1 | 2 | 3 | 0 |
| FIBR — Normal | 34 | 127 | 126 | 56 |
| FIBR — Above | 3 | 18 | 18 | 16 |
| HCT — Unknown | 1 | 2 | 1 | 0 |
| HCT — Below | 2 | 12 | 9 | 1 |
| HCT — Normal | 35 | 135 | 135 | 71 |
| HCT — Above | 0 | 1 | 4 | 1 |
| HGB — Unknown | 1 | 2 | 1 | 0 |
| HGB — Below | 1 | 6 | 7 | 1 |
| HGB — Normal | 36 | 141 | 137 | 70 |
| HGB — Above | 0 | 1 | 4 | 2 |
| LDH — Unknown | 0 | 0 | 0 | 0 |
| LDH — Below | 0 | 0 | 0 | 0 |
| LDH — Normal | 38 | 149 | 149 | 73 |
| LDH — Above | 0 | 1 | 0 | 0 |
| LYM — Unknown | 1 | 2 | 1 | 0 |
| LYM — Below | 1 | 2 | 1 | 1 |
| LYM — Normal | 35 | 146 | 145 | 72 |
| LYM — Above | 1 | 0 | 2 | 0 |
| MCV — Unknown | 1 | 2 | 1 | 0 |
| MCV — Below | 0 | 5 | 1 | 2 |
| MCV — Normal | 37 | 140 | 145 | 69 |
| MCV — Above | 0 | 3 | 2 | 2 |
| MON — Unknown | 1 | 2 | 1 | 0 |
| MON — Below | 1 | 6 | 4 | 2 |
| MON — Normal | 36 | 142 | 144 | 71 |
| MON — Above | 0 | 0 | 0 | 0 |
| NEU — Unknown | 1 | 2 | 1 | 0 |
| NEU — Below | 0 | 3 | 0 | 0 |
| NEU — Normal | 37 | 142 | 146 | 71 |
| NEU — Above | 0 | 3 | 2 | 2 |
| PTT — Unknown | 0 | 4 | 2 | 1 |
| PTT — Below | 1 | 10 | 5 | 1 |
| PTT — Normal | 36 | 135 | 137 | 70 |
| PTT — Above | 1 | 1 | 5 | 1 |
| PLAT — Unknown | 2 | 2 | 2 | 0 |
| PLAT — Below | 0 | 3 | 3 | 1 |
| PLAT — Normal | 35 | 144 | 143 | 70 |
| PLAT — Above | 1 | 1 | 1 | 2 |
| PT — Unknown | 0 | 4 | 2 | 1 |
| PT — Below | 2 | 7 | 2 | 3 |
| PT — Normal | 35 | 135 | 137 | 67 |
| PT — Above | 1 | 4 | 8 | 2 |
| RBC — Unknown | 1 | 2 | 1 | 0 |
| RBC — Below | 0 | 7 | 4 | 2 |
| RBC — Normal | 37 | 141 | 142 | 68 |
| RBC — Above | 0 | 0 | 2 | 3 |
| TP — Unknown | 0 | 0 | 0 | 0 |
| TP — Below | 0 | 0 | 0 | 0 |
| TP — Normal | 38 | 149 | 148 | 73 |
| TP — Above | 0 | 1 | 1 | 0 |
| WBC — Unknown | 1 | 2 | 1 | 0 |
| WBC — Below | 0 | 1 | 0 | 1 |
| WBC — Normal | 37 | 145 | 140 | 70 |
| WBC — Above | 0 | 2 | 8 | 2 |
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hematocrit (HCT), Hemoglobin (HGB), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Mean Corpuscular Volume (MCV), Monocytes (MON), Neutrophils (NEU), Partial Thromboplastin Time (PTT), Platelets (PLAT), Prothrombin Time (PT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
| Participants | Placebo Group | GSK1437173A Formulation 1 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 3 Group |
|---|---|---|---|---|
| ALT — Unknown | 0 | 0 | 0 | 0 |
| ALT — Below | 0 | 0 | 0 | 0 |
| ALT — Normal | 36 | 139 | 138 | 68 |
| ALT — Above | 2 | 4 | 6 | 4 |
| AST — Unknown | 0 | 0 | 0 | 1 |
| AST — Below | 0 | 0 | 0 | 0 |
| AST — Normal | 38 | 139 | 140 | 67 |
| AST — Above | 0 | 4 | 4 | 4 |
| BAS — Unknown | 1 | 3 | 2 | 2 |
| BAS — Below | 0 | 0 | 0 | 0 |
| BAS — Normal | 37 | 140 | 142 | 70 |
| BAS — Above | 0 | 0 | 0 | 0 |
| CAL — Unknown | 0 | 0 | 0 | 1 |
| CAL — Below | 0 | 2 | 1 | 0 |
| CAL — Normal | 38 | 137 | 136 | 71 |
| CAL — Above | 0 | 4 | 7 | 0 |
| CREA — Unknown | 0 | 0 | 0 | 1 |
| CREA — Below | 0 | 0 | 0 | 0 |
| CREA — Normal | 37 | 138 | 138 | 67 |
| CREA — Above | 1 | 5 | 6 | 4 |
| EOS — Unknown | 1 | 3 | 2 | 2 |
| EOS — Below | 1 | 12 | 12 | 7 |
| EOS — Normal | 35 | 125 | 129 | 62 |
| EOS — Above | 1 | 3 | 1 | 1 |
| FIBR — Unknown | 0 | 2 | 3 | 0 |
| FIBR — Below | 1 | 12 | 4 | 9 |
| FIBR — Normal | 34 | 124 | 131 | 59 |
| FIBR — Above | 3 | 5 | 6 | 4 |
| HCT — Unknown | 1 | 3 | 2 | 1 |
| HCT — Below | 2 | 12 | 11 | 4 |
| HCT — Normal | 35 | 126 | 126 | 65 |
| HCT — Above | 0 | 2 | 5 | 2 |
| HGB — Unknown | 1 | 3 | 2 | 1 |
| HGB — Below | 1 | 9 | 7 | 3 |
| HGB — Normal | 35 | 129 | 134 | 66 |
| HGB — Above | 1 | 2 | 1 | 2 |
| LDH — Unknown | 0 | 0 | 0 | 0 |
| LDH — Below | 0 | 0 | 0 | 0 |
| LDH — Normal | 38 | 143 | 144 | 71 |
| LDH — Above | 0 | 0 | 0 | 1 |
| LYM — Unknown | 1 | 3 | 2 | 2 |
| LYM — Below | 0 | 2 | 2 | 3 |
| LYM — Normal | 37 | 137 | 139 | 67 |
| LYM — Above | 0 | 1 | 1 | 0 |
| MCV — Unknown | 1 | 3 | 2 | 1 |
| MCV — Below | 0 | 2 | 1 | 3 |
| MCV — Normal | 37 | 134 | 139 | 67 |
| MCV — Above | 0 | 4 | 2 | 1 |
| MON — Unknown | 1 | 3 | 2 | 2 |
| MON — Below | 3 | 10 | 9 | 6 |
| MON — Normal | 34 | 130 | 133 | 64 |
| MON — Above | 0 | 0 | 0 | 0 |
| NEU — Unknown | 1 | 3 | 2 | 2 |
| NEU — Below | 1 | 3 | 1 | 1 |
| NEU — Normal | 36 | 136 | 138 | 68 |
| NEU — Above | 0 | 1 | 3 | 1 |
| PTT — Unknown | 0 | 2 | 3 | 0 |
| PTT — Below | 0 | 1 | 1 | 0 |
| PTT — Normal | 37 | 132 | 129 | 64 |
| PTT — Above | 1 | 8 | 11 | 8 |
| PLAT — Unknown | 1 | 3 | 4 | 2 |
| PLAT — Below | 1 | 3 | 5 | 0 |
| PLAT — Normal | 36 | 137 | 135 | 68 |
| PLAT — Above | 0 | 0 | 0 | 2 |
| PT — Unknown | 0 | 2 | 3 | 0 |
| PT — Below | 0 | 0 | 1 | 0 |
| PT — Normal | 37 | 136 | 132 | 67 |
| PT — Above | 1 | 5 | 8 | 5 |
| RBC — Unknown | 1 | 3 | 2 | 1 |
| RBC — Below | 1 | 8 | 10 | 3 |
| RBC — Normal | 36 | 131 | 131 | 66 |
| RBC — Above | 0 | 1 | 1 | 2 |
| TP — Unknown | 0 | 0 | 0 | 0 |
| TP — Below | 0 | 1 | 0 | 0 |
| TP — Normal | 38 | 142 | 144 | 72 |
| TP — Above | 0 | 0 | 0 | 0 |
| WBC — Unknown | 1 | 3 | 2 | 2 |
| WBC — Below | 1 | 6 | 0 | 1 |
| WBC — Normal | 35 | 133 | 139 | 67 |
| WBC — Above | 1 | 1 | 3 | 2 |
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hematocrit (HCT), Hemoglobin (HGB), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Mean Corpuscular Volume (MCV), Monocytes (MON), Neutrophils (NEU), Partial Thromboplastin Time (PTT), Platelets (PLAT), Prothrombin Time (PT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
| Participants | Placebo Group | GSK1437173A Formulation 1 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 3 Group |
|---|---|---|---|---|
| ALT — Unknown | 0 | 0 | 0 | 0 |
| ALT — Below | 0 | 0 | 0 | 0 |
| ALT — Normal | 36 | 138 | 139 | 70 |
| ALT — Above | 2 | 4 | 3 | 2 |
| AST — Unknown | 0 | 0 | 0 | 0 |
| AST — Below | 0 | 0 | 0 | 0 |
| AST — Normal | 38 | 139 | 140 | 70 |
| AST — Above | 0 | 3 | 2 | 2 |
| BAS — Unknown | 0 | 3 | 3 | 3 |
| BAS — Below | 0 | 0 | 0 | 0 |
| BAS — Normal | 38 | 139 | 139 | 69 |
| BAS — Above | 0 | 0 | 0 | 0 |
| CAL — Unknown | 0 | 0 | 0 | 0 |
| CAL — Below | 0 | 1 | 0 | 1 |
| CAL — Normal | 38 | 140 | 138 | 71 |
| CAL — Above | 0 | 1 | 4 | 0 |
| CREA — Unknown | 0 | 0 | 0 | 0 |
| CREA — Below | 0 | 0 | 0 | 0 |
| CREA — Normal | 37 | 135 | 134 | 68 |
| CREA — Above | 1 | 7 | 8 | 4 |
| EOS — Unknown | 0 | 3 | 3 | 3 |
| EOS — Below | 1 | 7 | 13 | 11 |
| EOS — Normal | 36 | 131 | 122 | 57 |
| EOS — Above | 1 | 1 | 4 | 1 |
| FIBR — Unknown | 0 | 3 | 0 | 2 |
| FIBR — Below | 1 | 5 | 4 | 2 |
| FIBR — Normal | 35 | 125 | 133 | 61 |
| FIBR — Above | 2 | 9 | 5 | 7 |
| HCT — Unknown | 0 | 3 | 3 | 4 |
| HCT — Below | 4 | 12 | 10 | 6 |
| HCT — Normal | 34 | 126 | 126 | 61 |
| HCT — Above | 0 | 1 | 3 | 1 |
| HGB — Unknown | 0 | 3 | 3 | 3 |
| HGB — Below | 2 | 10 | 5 | 3 |
| HGB — Normal | 35 | 127 | 133 | 65 |
| HGB — Above | 1 | 2 | 1 | 1 |
| LDH — Unknown | 0 | 0 | 0 | 0 |
| LDH — Below | 0 | 0 | 0 | 0 |
| LDH — Normal | 38 | 141 | 142 | 71 |
| LDH — Above | 0 | 1 | 0 | 1 |
| LYM — Unknown | 0 | 3 | 3 | 3 |
| LYM — Below | 0 | 3 | 2 | 1 |
| LYM — Normal | 38 | 136 | 136 | 68 |
| LYM — Above | 0 | 0 | 1 | 0 |
| MCV — Unknown | 0 | 3 | 3 | 4 |
| MCV — Below | 0 | 3 | 1 | 4 |
| MCV — Normal | 38 | 133 | 137 | 63 |
| MCV — Above | 0 | 3 | 1 | 1 |
| MON — Unknown | 0 | 3 | 3 | 3 |
| MON — Below | 0 | 9 | 13 | 8 |
| MON — Normal | 38 | 130 | 126 | 61 |
| MON — Above | 0 | 0 | 0 | 0 |
| NEU — Unknown | 0 | 3 | 3 | 3 |
| NEU — Below | 0 | 4 | 0 | 0 |
| NEU — Normal | 38 | 135 | 138 | 65 |
| NEU — Above | 0 | 0 | 1 | 4 |
| PTT — Unknown | 0 | 3 | 0 | 2 |
| PTT — Below | 0 | 0 | 0 | 0 |
| PTT — Normal | 37 | 131 | 136 | 68 |
| PTT — Above | 1 | 8 | 6 | 2 |
| PLAT — Unknown | 1 | 7 | 3 | 4 |
| PLAT — Below | 0 | 4 | 4 | 1 |
| PLAT — Normal | 37 | 131 | 134 | 66 |
| PLAT — Above | 0 | 0 | 1 | 1 |
| PT — Unknown | 0 | 3 | 0 | 2 |
| PT — Below | 0 | 0 | 0 | 0 |
| PT — Normal | 37 | 131 | 137 | 68 |
| PT — Above | 1 | 8 | 5 | 2 |
| RBC — Unknown | 0 | 3 | 3 | 4 |
| RBC — Below | 2 | 7 | 8 | 2 |
| RBC — Normal | 36 | 131 | 131 | 64 |
| RBC — Above | 0 | 1 | 0 | 2 |
| TP — Unknown | 0 | 0 | 0 | 0 |
| TP — Below | 0 | 0 | 0 | 0 |
| TP — Normal | 38 | 142 | 142 | 72 |
| TP — Above | 0 | 0 | 0 | 0 |
| WBC — Unknown | 0 | 3 | 3 | 3 |
| WBC — Below | 0 | 6 | 2 | 2 |
| WBC — Normal | 37 | 132 | 137 | 64 |
| WBC — Above | 1 | 1 | 0 | 3 |
Collected over Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6); Unsolicited AEs: during the 30-day post-vaccination period (Days 0-29); SAEs: during the entire study period (Day 0 - Month 14).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Group | 0/38 (0%) | 3/38 (7.9%) | 9/38 (23.7%) |
| GSK1437173A Formulation 3 Group | 2/73 (2.7%) | 8/73 (11%) | 31/73 (42.5%) |
| GSK1437173A Formulation 2 Group | 0/149 (0%) | 6/149 (4%) | 114/149 (76.5%) |
| GSK1437173A Formulation 1 Group | 1/150 (0.7%) | 10/150 (6.7%) | 131/150 (87.3%) |
| Event | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| Hiatus herniaGastrointestinal disorders | 1/38 | 0/73 | 0/149 | 0/150 |
| CholelithiasisHepatobiliary disorders | 1/38 | 1/73 | 0/149 | 0/150 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/38 | 0/73 | 1/149 | 0/150 |
| Acute myocardial infarctionCardiac disorders | 0/38 | 1/73 | 0/149 | 0/150 |
| Cardiac failureCardiac disorders | 0/38 | 1/73 | 0/149 | 0/150 |
| Coronary artery occlusionCardiac disorders | 0/38 | 1/73 | 0/149 | 0/150 |
| HerniaGeneral disorders | 0/38 | 1/73 | 0/149 | 0/150 |
| Bile duct obstructionHepatobiliary disorders | 0/38 | 1/73 | 0/149 | 0/150 |
| DiverticulitisInfections and infestations | 0/38 | 1/73 | 0/149 | 0/150 |
| Escherichia sepsisInfections and infestations | 0/38 | 1/73 | 0/149 | 0/150 |
| Event | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group |
|---|---|---|---|---|
| PainGeneral disorders | 3/38 | 14/73 | 104/149 | 126/150 |
| FatigueGeneral disorders | 7/38 | 16/73 | 52/149 | 73/150 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/38 | 12/73 | 49/149 | 63/150 |
| HeadacheNervous system disorders | 5/38 | 11/73 | 37/149 | 57/150 |
| ErythemaSkin and subcutaneous tissue disorders | 0/38 | 3/73 | 27/149 | 47/150 |
| PyrexiaGeneral disorders | 1/38 | 0/73 | 18/149 | 26/150 |
| SwellingGeneral disorders | 0/38 | 3/73 | 25/149 | 24/150 |
| Gastrointestinal disorderGastrointestinal disorders | 3/38 | 5/73 | 18/149 | 17/150 |
| ChillsGeneral disorders | 0/38 | 0/73 | 3/149 | 8/150 |
| Age, Continuous(Years) | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group | Total |
|---|---|---|---|---|---|
| Mean | 65.0 ± 9.0 | 65.1 ± 8.7 | 65.1 ± 9.9 | 65.0 ± 8.9 | 65.0 ± 9.2 |
| Sex: Female, Male(Participants) | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group | Total |
|---|---|---|---|---|---|
| Female | 22 | 40 | 89 | 81 | 232 |
| Male | 16 | 33 | 60 | 69 | 178 |
| Race/Ethnicity, Customized(Participants) | Placebo Group | GSK1437173A Formulation 3 Group | GSK1437173A Formulation 2 Group | GSK1437173A Formulation 1 Group | Total |
|---|---|---|---|---|---|
| Race/Ethnicity — African Heritage / African American | 0 | 1 | 2 | 6 | 9 |
| Race/Ethnicity — American Indian or Alaskan Native | 0 | 0 | 1 | 2 | 3 |
| Race/Ethnicity — Other | 0 | 0 | 0 | 1 | 1 |
| Race/Ethnicity — White - Arabic / North African Heritage | 0 | 0 | 1 | 0 | 1 |
| Race/Ethnicity — White - Caucasian / European Heritage | 38 | 72 | 145 | 141 | 396 |
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jan 2009 to primary completion in Jul 2010, 17 months.
Results were first posted in Dec 2017, 7 years 5 months after primary completion. A results delay was requested in Nov 2009.
Of 22 phase 2 interventional studies under Herpes Zoster, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 27. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Shingrix